Cyclic and Linear Peptides: What Cyclisation Changes

Cyclisation is one of the most consequential modifications available to a peptide chemist. It changes stability, selectivity and — often overlooked — how the compound has to be analysed.

How peptides are cyclised

Three routes are common. A disulfide bridge between two cysteine residues is the mildest and is reversible under reducing conditions. A lactam bridge between a side-chain amine and a side-chain carboxyl is covalent and not reversible in the same way. Head-to-tail cyclisation joins the N- and C-termini directly, eliminating both free ends.

Which route was used matters practically, because a disulfide-cyclised peptide can be opened by a reducing agent in your buffer while a lactam-bridged one cannot.

What it buys

Removing free termini removes the substrate for exopeptidases, so cyclic peptides are generally more stable. Constraining the backbone also reduces the conformational space the molecule can occupy, which frequently improves receptor selectivity: a constrained conformation may fit one receptor subtype well and another poorly. This is the basis of much of the selectivity engineering discussed in our note on melanocortin receptor subtypes.

What it costs analytically

Cyclic peptides complicate purity analysis in ways linear sequences do not.

The open-chain form has the same amino acid composition and nearly the same mass — differing by two hydrogens for a disulfide — so it can co-elute or elute very close to the target. Dimeric and oligomeric forms, where the bridge forms between two molecules rather than within one, are also possible and share the monomer’s composition entirely.

The consequence is that retention time alone is weak evidence of identity for a cyclic compound, and a purity percentage from a single chromatographic run may not resolve the isomers. Mass confirmation is the check that distinguishes them.

What to look for on a certificate

For any cyclic peptide, confirm that identity was established by mass and not by retention time alone, and check whether the analysis addressed oligomeric forms. Our notes on HPLC and mass spectrometry and why certificates disagree on purity cover the reasoning.

Storage

Avoid reducing agents in buffers used with disulfide-cyclised peptides, and minimise headspace oxygen for peptides containing free cysteine, where oxidation can form unintended bridges. General guidance is in storage and stability.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice or a suggestion of human or veterinary use. Certificates of analysis are published on this site.